Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors

Area of Science:

• Molecular Biology
• Cell Signaling
• Biochemistry

Background:

• Bone morphogenetic proteins (BMPs) are crucial secreted cytokines regulating cell fate and function.
• BMPs signal through heteromeric complexes of BMP type I and type II serine/threonine kinase receptors.
• Auxiliary receptors like Endoglin and RGMs modulate BMP ligand-receptor interactions.

Purpose of the Study:

• To review the identification, structure, and function of BMP receptors (BMPRs) in health and disease.
• To highlight the role of BMPR gene mutations in human pathologies.
• To discuss the therapeutic potential of selective BMPR kinase inhibitors.

Main Methods:

• Literature review of BMPR identification, structure, and function.
• Analysis of genetic mutations in BMPR-encoding genes and associated diseases.
• Exploration of small molecule inhibitors targeting BMPR kinase activity.

Main Results:

• BMPRs, including BMPRIA and BMPRII, mediate cellular responses via SMAD effectors.
• Loss-of-function mutations in BMPRII, Endoglin, and RGMc cause pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, and juvenile hemochromatosis.
• Gain-of-function mutations in ACVR1 (ALK2) are implicated in Fibrodysplasia ossificans progressiva and diffuse intrinsic pontine glioma.

Conclusions:

• BMPR signaling pathways are critical in maintaining cellular homeostasis and are implicated in numerous diseases.
• Understanding BMPR function and mutation-driven pathologies is essential for therapeutic development.
• Selective BMPR kinase inhibitors represent a promising therapeutic strategy for diseases driven by aberrant BMP signaling.